These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Angiotensin II type 1 receptor blocker attenuates exacerbated left ventricular remodeling and failure in diabetes-associated myocardial infarction. Matsusaka H, Kinugawa S, Ide T, Matsushima S, Shiomi T, Kubota T, Sunagawa K, Tsutsui H. J Cardiovasc Pharmacol; 2006 Sep 11; 48(3):95-102. PubMed ID: 17031262 [Abstract] [Full Text] [Related]
11. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Doerries C, Grote K, Hilfiker-Kleiner D, Luchtefeld M, Schaefer A, Holland SM, Sorrentino S, Manes C, Schieffer B, Drexler H, Landmesser U. Circ Res; 2007 Mar 30; 100(6):894-903. PubMed ID: 17332431 [Abstract] [Full Text] [Related]
12. Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. Shiomi T, Tsutsui H, Matsusaka H, Murakami K, Hayashidani S, Ikeuchi M, Wen J, Kubota T, Utsumi H, Takeshita A. Circulation; 2004 Feb 03; 109(4):544-9. PubMed ID: 14744974 [Abstract] [Full Text] [Related]
13. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A, Spiekermann S, Hilfiker-Kleiner D, Templin C, Kotlarz D, Mueller M, Fuchs M, Hornig B, Haller H, Drexler H. Circulation; 2004 Oct 05; 110(14):1933-9. PubMed ID: 15466656 [Abstract] [Full Text] [Related]
14. Adiponectin determines farnesoid X receptor agonism-mediated cardioprotection against post-infarction remodelling and dysfunction. Xia Y, Zhang F, Zhao S, Li Y, Chen X, Gao E, Xu X, Xiong Z, Zhang X, Zhang J, Zhao H, Wang W, Wang H, Guo Y, Liu Y, Li C, Wang S, Zhang L, Yan W, Tao L. Cardiovasc Res; 2018 Aug 01; 114(10):1335-1349. PubMed ID: 29668847 [Abstract] [Full Text] [Related]
18. The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Lygate CA, Hulbert K, Monfared M, Cole MA, Clarke K, Neubauer S. Cardiovasc Res; 2003 Jun 01; 58(3):632-7. PubMed ID: 12798436 [Abstract] [Full Text] [Related]